Recombinant botulinum neurotoxin serotype A1 in vivo characterization
Abstract Clinically used botulinum neurotoxins (BoNTs) are natural products of Clostridium botulinum. A novel, recombinant BoNT type A1 (rBoNT/A1; IPN10260) has been synthesized using the native amino acid sequence expressed in Escherichia coli and has previously been characterized in vitro and ex v...
Saved in:
Main Authors: | Cindy Périer (Author), Vincent Martin (Author), Sylvie Cornet (Author), Christine Favre‐Guilmard (Author), Marie‐Noelle Rocher (Author), Julien Bindler (Author), Stéphanie Wagner (Author), Emile Andriambeloson (Author), Brian B. Rudkin (Author), Rudy Marty (Author), Alban Vignaud (Author), Matthew Beard (Author), Stephane Lezmi (Author), Mikhail Kalinichev (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2021-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Development and evaluation of candidate subunit vaccine against botulinum neurotoxin serotype B
by: Dan-Yang Shi, et al.
Published: (2019) -
Development and evaluation of candidate subunit vaccine and novel antitoxin against botulinum neurotoxin serotype E
by: Dan-Yang Shi, et al.
Published: (2020) -
Botulinum neurotoxin formulations: overcoming the confusion
by: Samizadeh S, et al.
Published: (2018) -
Botulinum Neurotoxins and Nervous System Future Challenges for Novel Indications
Published: (2020) -
Botulinum neurotoxin formulations: overcoming the confusion [Corrigendum]
by: Samizadeh S, et al.
Published: (2018)